1425038-23-8

Basic information

• Product Name: methyl (33R,35S,91R,92R,5S,Z)-5-(tert-butyl)-17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopropanacyclotetradecaphan-12-yne-35-carboxylate
• Synonyms: methyl (33R,35S,91R,92R,5S,Z)-5-(tert-butyl)-17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopropanacyclotetradecaphan-12-yne-35-carboxylate;(1aR,5S,8S,10R,22aR)-18,19-Didehydro-5-(1,1-dimethylethyl)-1,1a,3,4,5,6,9,10,20,21,22,22a-dodecahydro-14-methoxy-3,6-dioxo-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxylic acid methyl ester
• CAS NO: 1425038-23-8
• Molecular Formula: C30H36N4O7
• Molecular Weight: 564.63
• Mol File: 1425038-23-8.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: methyl (33R,35S,91R,92R,5S,Z)-5-(tert-butyl)-17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopropanacyclotetradecaphan-12-yne-35-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl (33R,35S,91R,92R,5S,Z)-5-(tert-butyl)-17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopropanacyclotetradecaphan-12-yne-35-carboxylate(1425038-23-8)
• EPA Substance Registry System: methyl (33R,35S,91R,92R,5S,Z)-5-(tert-butyl)-17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopropanacyclotetradecaphan-12-yne-35-carboxylate(1425038-23-8)

Safety Data

• Hazardous Substances Data: 1425038-23-8(Hazardous Substances Data)

Usage

General Description

Methyl (33R,35S,91R,92R,5S,Z)-5-(tert-butyl)-17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopropanacyclotetradecaphan-12-yne-35-carboxylate is a complex chemical compound with various functional groups. It contains a methyl group, a tert-butyl group, and a methoxy group, as well as carbonyl and ester functional groups. The compound also features a complex ring structure consisting of a pyrrolidina, cyclopropane, and quinoxalinone, among others. This chemical may have potential uses in pharmaceuticals, materials science, or other fields due to its unique structure and potential reactivity.

Upstream product

• 1361028-94-5 methyl (4R)-4-[(3-chloro-7-methoxyquinoxalin-2-yl)oxy]-L-prolinate hydrochloride 
• 1224174-07-5 (S)-1-chlorohept-6-en-2-ol 
• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 
• 1425038-21-6 (S)-3,3-dimethyl-2-((((1R,2R)-2-(pent-4-yn-1-yl)cyclopropoxy)carbonyl)amino)butanoic acid tert-butylamine salt 
• 1425038-19-2 (S)-3,3-dimethyl-2-(((1R,2R)-2-(pent-4-ynyl)cyclopropoxy)carbonylamino)butanoic acid 
• 1350619-77-0 (1R,2R)-2-(pent-4-yn-1-yl)cyclopropan-1-ol 
• 1206524-79-9 1-(tert-butyl) 2-methyl (2S,4R)-4-((3-chloro-7-methoxyquinoxalin-2-yl)oxy)pyrrolidine-1,2-dicarboxylate 
• 1425038-22-7 (S )-2-(((1R,2R)-2-(5-(6-methoxy-3-((3R,5S)-5-(methoxycarbonyl)pyrrolidin-3-yloxy)quinoxalin-2-yl)pent-4-ynyl)cyclopropoxy)carbonylamino)-3,3-dimethylbutanoicacid 
• 1425038-20-5 (2S,4R)-4-[(3-chloro-7-methoxyquinoxalin-2-yl)oxy]-2-(methoxycarbonyl)pyrrolidin-1-ium methanesulfonate 
• 39267-04-4 2,3-dichloro-6-methoxyquinoxaline 
• 31910-18-6 2,3-dihydroxy-6-methoxyquinoxaline 
• 59548-39-9 4-methoxyphenylene-1,2-diamine dihydrochloride 

Downstream Products

• 1206524-85-7 (1aR,5S,8S,10R,22aR)-5-tert-butyl-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradeca-hydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxylic acid hydrate 
• 1350514-68-9 grazoprevir 
• 1206524-84-6 methyl (1aR,5S,8S,10R,22aR)-5-tert-butyl-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxa-diazacyclononadecino[11,12-b]quinoxaline-8-carboxylate 

Relevant articles and documents

Synthesis of Grazoprevir, a Potent NS3/4a Protease Inhibitor for the Treatment of Hepatitis C Virus

An efficient synthesis of grazoprevir is reported. Starting from four readily available building blocks, grazoprevir is prepared in 51% overall yield and >99.9% purity for pharmaceutical use.

METHODS AND INTERMEDIATES FOR THE PREPARATION OF MACROLACTAMS

The present invention relates to synthetic processes useful in the preparation of macrolactams that inhibit hepatitis C virus (HCV), specifically macrolactam compounds that inhibit the HCV NS3 protease activity and have application in the treatment of conditions caused by HCV. The present invention also encompasses intermediates useful in the disclosed synthetic processes and the methods of their preparation.

Inhibitors of nedd8-activating enzyme

The invention relates to an administration unit comprising crystalline form I of {(1 S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate (I-216) hydrochloride salt and to a packaging comprising the administration unit according to the invention.